glp-1 drug market size share of RAs in 2016 and 2017 Market insights: How to analyze

However, the reduction in HbA1c was non-significantly diminished with exenatide twice-daily in the small subset of patients (5%) with higher titers

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

10.1093/eurheartj/ehae508 88

Additionally, follow-up at 31 weeks showed no difference in eGFR between the placebo and oral-semaglutide groups compared with baseline eGFR measurements, suggesting that treatment had no adverse effects on kidney function

A study involving patients with T2DM by Zander et al

Furthermore, they also found that 'a balanced dual agonist in mice engineered to lack GLP-1 receptors still induced weight loss, proving that the compounds were not causing weight loss purely by targeting GLP-1' (Molteni, Chen)